Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship.
chi-Conopeptide MrIA (chi-MrIA) is a 13-residue peptide contained in the venom of the predatory marine snail Conus marmoreus that has been found to inhibit the norepinephrine transporter (NET). We investigated whether chi-MrIA targeted the other members of the monoamine transporter family and found no effect of the peptide (100 microM) on the activity of the dopamine transporter and the serotonin transporter, indicating a high specificity of action. The binding of the NET inhibitors, [3H]nisoxetine and [3H]mazindol, to the expressed rat and human NET was inhibited by chi-MrIA with the conopeptide displaying a slight preference toward the rat isoform. For both radioligands, saturation binding studies showed that the inhibition by chi-MrIA was competitive in nature. It has previously been demonstrated that chi-MrIA does not compete with norepinephrine, unlike classically described NET inhibitors such as nisoxetine and mazindol that do. This pattern of behavior implies that the binding site for chi-MrIA on the NET overlaps the antidepressant binding site and is wholly distinct from the substrate binding site. The inhibitory effect of chi-MrIA was found to be dependent on Na+ with the conopeptide becoming a less effective blocker of [3H]norepinephrine by the NET under the conditions of reduced extracellular Na+. In this respect, chi-MrIA is similar to the antidepressant inhibitors of the NET. The structure-activity relationship of chi-MrIA was investigated by alanine scanning. Four residues in the first cysteine-bracketed loop of chi-MrIA and a His in loop 2 played a dominant role in the interaction between chi-MrIA and the NET. H alpha chemical shift comparisons indicated that side-chain interactions at these key positions were structurally perturbed by the replacement of Gly-6. From these data, we present a model of the structure of chi-MrIA that shows the relative orientation of the key binding residues. This model provides a new molecular caliper for probing the structure of the NET.
Sharpe
Iain A
IA
Institute for Molecular Bioscience and School of Biomedical Sciences, The University of Queensland, St. Lucia 4072, Queensland, Australia.
Palant
Elka
E
Schroeder
Christina I
CI
Kaye
David M
DM
Adams
David J
DJ
Alewood
Paul F
PF
Lewis
Richard J
RJ
D000595:Amino Acid Sequence; D000818:Animals; D019556:COS Cells; D020916:Conotoxins / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008958:Models, Molecular; D008978:Mollusk Venoms / Q000737:chemistry / Q000494:pharmacology*; D050484:Norepinephrine Plasma Membrane Transport Proteins; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D055672:Static Electricity; D013329:Structure-Activity Relationship; D027981:Symporters / Q000037:antagonists & inhibitors*
D020916:Conotoxins; D008978:Mollusk Venoms; D050484:Norepinephrine Plasma Membrane Transport Proteins; D009842:Oligopeptides; D011994:Recombinant Proteins; C493227:SLC6A2 protein, human; C493226:Slc6a2 protein, rat; D027981:Symporters